Piaditis George, Markou Athina, Papanastasiou Labrini, Androulakis Ioannis I, Kaltsas Gregory
Department of Endocrinology and Diabetes CenterG. Gennimatas Hospital, 154 Mesogion Avenue, 11527 Holargos, Athens, Greece andDepartment of PathophysiologyNational University of Athens, Mikras Asias 75, 11527 Athens, Greece
Department of Endocrinology and Diabetes CenterG. Gennimatas Hospital, 154 Mesogion Avenue, 11527 Holargos, Athens, Greece andDepartment of PathophysiologyNational University of Athens, Mikras Asias 75, 11527 Athens, Greece.
Eur J Endocrinol. 2015 May;172(5):R191-203. doi: 10.1530/EJE-14-0537. Epub 2014 Dec 23.
Primary aldosteronism (PA) secondary to excessive and/or autonomous aldosterone secretion from the renin-angiotensin system accounts for ∼10% of cases of hypertension and is primarily caused by bilateral adrenal hyperplasia (BAH) or aldosterone-producing adenomas (APAs). Although the diagnosis has traditionally been supported by low serum potassium levels, normokalaemic and even normotensive forms of PA have been identified expanding further the clinical phenotype. Moreover, recent evidence has shown that serum aldosterone correlates with increased blood pressure (BP) in the general population and even moderately raised aldosterone levels are linked to increased cardiovascular morbidity and mortality. In addition, aldosterone antagonists are effective in BP control even in patients without evidence of dysregulated aldosterone secretion. These findings indicate a higher prevalence of aldosterone excess among hypertensive patients than previously considered that could be attributed to disease heterogeneity, aldosterone level fluctuations related to an ACTH effect or inadequate sensitivity of current diagnostic means to identify apparent aldosterone excess. In addition, functioning aberrant receptors expressed in the adrenal tissue have been found in a subset of PA cases that could also be related to its pathogenesis. Recently a number of specific genetic alterations, mainly involving ion homeostasis across the membrane of zona glomerulosa, have been detected in ∼50% of patients with APAs. Although specific genotype/phenotype correlations have not been clearly identified, differential expression of these genetic alterations could also account for the wide clinical phenotype, variations in disease prevalence and performance of diagnostic tests. In the present review, we critically analyse the current means used to diagnose PA along with the role that ACTH, aberrant receptor expression and genetic alterations may exert, and provide evidence for an increased prevalence of aldosterone dysregulation in patients with essential hypertension and pre-hypertension.
原发性醛固酮增多症(PA)继发于肾素 - 血管紧张素系统醛固酮分泌过多和/或自主性分泌,约占高血压病例的10%,主要由双侧肾上腺增生(BAH)或醛固酮瘤(APA)引起。虽然传统上诊断依据是血清钾水平降低,但现已发现正常血钾甚至血压正常的PA形式,进一步扩展了临床表型。此外,最近的证据表明,在普通人群中血清醛固酮与血压升高相关,即使醛固酮水平适度升高也与心血管发病率和死亡率增加有关。此外,醛固酮拮抗剂即使对无醛固酮分泌失调证据的患者,在控制血压方面也有效。这些发现表明,高血压患者中醛固酮过量的患病率高于先前认为的,这可能归因于疾病异质性、与促肾上腺皮质激素(ACTH)效应相关的醛固酮水平波动或当前诊断手段识别明显醛固酮过量的敏感性不足。此外,在一部分PA病例中发现肾上腺组织中存在功能异常的受体,这也可能与其发病机制有关。最近,在约50%的APA患者中检测到一些特定的基因改变,主要涉及球状带细胞膜上的离子稳态。虽然尚未明确确定特定的基因型/表型相关性,但这些基因改变的差异表达也可能解释广泛的临床表型、疾病患病率差异和诊断测试的表现。在本综述中,我们批判性地分析了目前用于诊断PA的方法以及ACTH、异常受体表达和基因改变可能发挥的作用,并为原发性高血压和高血压前期患者中醛固酮失调患病率增加提供了证据。